Merck receives FDA approval for ISENTRESS® (raltegravir) for pediatric oral suspension
ISENTRESS is now indicated in combination with other antiretroviral (ARV)…
8 January 2014 | By Merck
ISENTRESS is now indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients four weeks of age and older...